WTO Price Transparency Talks Face Resistance From Developed Countries
Executive Summary
Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.
You may also be interested in...
New Italian Pricing Decree To Drive R&D Transparency
Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.
EU Valletta Alliance Ups The Ante On Drug Pricing Transparency
EU countries should use a milestone World Health Organization resolution calling for more transparency on net medicine prices to help secure better access to medicine, says the Valletta group.
More Drug Price Disclosure In Store As WHO Delegates Pass Landmark Resolution
Many see the World Health Assembly resolution on drug pricing transparency as a game changer and welcome the fact that it will shine light on an area that critics says is far too opaque. Some are unhappy that the final version is not as strong as the original draft, but industry will be relieved the WHA ultimately did not adopt a requirement for mandatory disclosure of R&D costs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
